Fluoxetine Exposure during Adolescence Alters Responses to Aversive Stimuli in Adulthood

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1523/jneurosci.5725-12.2014">http://dx.doi.org/10.1523/jneurosci.5725-12.2014</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>Society for Neuroscience</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Fri Dec 21 20:54:36 EST 2018</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/88542">http://hdl.handle.net/1721.1/88542</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Fluoxetine Exposure during Adolescence Alters Responses to Aversive Stimuli in Adulthood

Sergio D. Iñiguez,1 Lyonna F. Alcantara,2 Brandon L. Warren,2 Lace M. Riggs,1 Eric M. Parise,2 Vincent Vialou,3 Katherine N. Wright,2 Genesis Dayrit,1 Steven J. Nieto,1 Matthew B. Wilkinson,3 Mary K. Lobo,1 Rachael L. Neve,5 Eric J. Nestler,1 and Carlos A. Bolaños-Guzmán2

1Department of Psychology, California State University, San Bernardino, California 92407, 2Department of Psychology and Program in Neuroscience, Florida State University, Tallahassee, Florida 32306, 3Fishberg Department of Neuroscience, Mount Sinai School of Medicine, New York, New York 10029, 4Department of Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, Maryland 21201, and 5Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

The mechanisms underlying the enduring neurobiological consequences of antidepressant exposure during adolescence are poorly understood. Here, we assessed the long-term effects of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, during adolescence on behavioral reactivity to emotion-eliciting stimuli. We administered FLX (10 mg/kg, bi-daily, for 15 d) to male adolescent [postnatal day 35 (P35) to P49] C57BL/6 mice. Three weeks after treatment (P70), reactivity to aversive stimuli (i.e., social defeat stress, forced swimming, and elevated plus maze) was assessed. We also examined the effects of FLX on the expression of extracellular signal-regulated kinase (ERK) 1/2-related signaling within the ventral tegmental area (VTA) of adolescent mice and Sprague Dawley rats. Adolescent FLX exposure suppressed depression-like behavior, as measured by the social interaction and forced swim tests, while enhancing anxiety-like responses in the elevated plus maze in adulthood. This complex behavioral profile was accompanied by decreases in ERK2 mRNA and protein phosphorylation within the VTA, while stress alone resulted in opposite neurobiological effects. Pharmacological (U0126) inhibition, as well as virus-mediated downregulation of ERK within the VTA mimicked the antidepressant-like profile observed after juvenile FLX treatment. Conversely, overexpression of ERK2 induced a depressive-like response, regardless of FLX pre-exposure. These findings demonstrate that exposure to FLX during adolescence modulates responsiveness to emotion-eliciting stimuli in adulthood, at least partially, via long-lasting adaptations in ERK-related signaling within the VTA. Our results further delineate the role ERK plays in regulating mood-related behaviors across the lifespan.

Key words: anxiety; depression; ERK; MAPK; SSRI; stress

Introduction

Major depressive disorder (MDD) affects up to 8% of the juvenile population (Kapornai and Vetró, 2008), resulting in negative functional consequences that extend into adulthood (Birmaher et al., 2007). Prozac [fluoxetine (FLX)], a selective serotonin reuptake inhibitor, is a therapeutic agent approved by the Food and Drug Administration to treat pediatric MDD (Hammerness et al., 2006). This has led to a significant increase in the prescription rate of FLX in this population (Zito et al., 2006), even though the majority of testing regarding its effectiveness and safety has been conducted in adults (Coyle et al., 2003; Olivier et al., 2011). This is remarkable given the pivotal role that the serotonin system plays in the regulation of brain development (Blakemore and Choudhury, 2006; Azmitia, 2007), that pharmacodynamic differences between developing and adult organisms are consistently reported (Iñiguez et al., 2008a; Correll et al., 2011; Neville et al., 2011), and that early-life pharmacological intervention often results in life-long neurobehavioral alterations (Bolaños et al., 2003b; Halladay et al., 2009; Oberlander et al., 2009).

The long-lasting functional consequences of FLX exposure during adolescence have recently begun to be elucidated. Juvenile FLX treatment enhances sensitivity to anxiety-eliciting environments (Homberg et al., 2011) while decreasing reactivity to acute inescapable stress conditions in adulthood (Karpova et al., 2009; Iñiguez et al., 2010a). The neurobiological mechanisms underlying these effects are unknown. Nevertheless, the antidepressant mechanisms of FLX have been linked to adaptations in postreceptor signaling since chronic, not acute, administration is required for its therapeutic effects (Berton and Nestler, 2006; Racagni and Popoli, 2008). For example, within the ventral teg-
mental area (VTA), a brain region implicated in mood regulation (Nestler and Carlezon, 2006; Chaudhury et al., 2013), brain-derived neurotrophic factor (BDNF) and its downstream signaling effectors are compromised in preclinical models of stress (Eisch et al., 2003), as well as in postmortem VTA samples from MDD patients (Krishnan et al., 2008). Conversely, chronic administration of FLX normalizes these alterations within the VTA (Krishnan et al., 2008; Cao et al., 2010). The extracellular signal-regulated kinase (ERK) 1/2, a downstream target of BDNF (Nunakawa et al., 2010), has been implicated in mediating the deleterious effects of stress (Gourley et al., 2008; Iniguez et al., 2010b), a major predisposing factor for MDD (de Kloet et al., 2005). ERK is activated by the binding of BDNF to tyrosine kinase receptor-B via the Ras-dependent cascade, inducing phosphorylation (p) of transcription factors such as cAMP response element-binding protein (CREB; Mazzucchelli and Brambilla, 2000). Therefore, it is conceivable that the functional effects observed in adulthood after juvenile FLX exposure may be mediated by long-lasting adaptations in ERK signaling within the VTA.

Given the prevalence of antidepressant prescriptions to adolescents and the scarcity of knowledge regarding the long-term effects of such treatments, it is essential that the neurobiological consequences associated with FLX exposure be elucidated. Thus, this study was designed to assess the impact of adolescent FLX exposure on behavioral responsivity to emotion-eliciting situations in adulthood, and to begin establishing causal relationships between the enduring FLX-induced antidepressant-like phenotype and ERK activity within the VTA.

Materials and Methods

Animals. For all experiments, animals were male, fed ad libitum, and housed at 23–25°C on a 12 h light/dark cycle (lights on between 7:00 A.M. and 7:00 P.M.). C57BL/6 mice and Sprague Dawley rats were obtained from the breeding colony at California State University, San Bernardino (CSUSB), while CD1 retired breeders were purchased from Charles River. C57BL/6 mice (four per cage), rats (two per cage), and CD1 mice (one per cage) were housed in clear polypropylene boxes containing wood shavings. Experiments were conducted in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and with approval of the Institutional Animal Care and Use Committee at CSUSB.

Drug treatment and experimental design. FLX was obtained from Sigma-Aldrich, dissolved in sterile distilled water [vehicle (VEH)], and administered in a volume of 2 ml/kg. The different experimental groups used in this study are listed in Table 1. Separate groups of adolescent mice were treated with VEH or FLX (10 mg/kg, twice daily) 4 h apart for 15 consecutive days [postnatal day 35 (P35) to P49]. The age at the start and duration of the experimental manipulation in both mice and rats (P35–P49) was selected because it roughly approximates mid-adolescence in humans (Andersen, 2003; Abreu-Villacca et al., 2010), a developmental stage in which the onset of MDD is most often reported (Burke et al., 1990; Paus et al., 2008) The drug regimen (20 mg/kg/d) was selected because it yields significant effects on behavior and gene expression in rodents (Englander et al., 2005; Iniguez et al., 2010a; LaPlant et al., 2010; Surget et al., 2011). After FLX treatment, responsiveness to behavioral despair-related (i.e., social defeat, forced swimming) and anxiety-related [i.e., elevated plus maze (EPM)] stimuli was assessed in adulthood (P70; Table 1, groups 1–6).

To examine how FLX treatment during adolescence influenced ERK expression within the VTA, separate groups of mice and rats were treated under the same drug regimen, and killed either 24 h after treatment or upon reaching adulthood (groups 7–11). To assess the effects of inescapable stress on ERK signaling within the VTA, a separate group of adolescent mice was treated with VEH (P35–P49), exposed to 10 d of social defeat stress in adulthood (P70–P79), and killed at P80 (group 12). Also, to start building causal relationships between ERK activity and behavioral reactivity to stressors, we selectively manipulated ERK activity by infusing U0126 (Sigma-Aldrich), a pharmacological inhibitor of ERK (group 13), or a herpes simplex virus (HSV) vector encoding green fluorescent protein (GFP; control), a dominant negative mutant of ERK2 (HSV-dnERK2), or a wild-type form of ERK2 (HSV-wtERK2) within the VTA of VEH- or FLX-treated mice (groups 14–15; see Virus vectors and reversal experiments). Last, separate groups of P47 drug-naive rats were infused with the HSV vectors to determine whether ERK activity within the adolescent VTA modulates responsiveness to aversive stimuli (groups 16–17) in an age-dependent manner. All behaviors were video recorded and scored by video-tracking software (Noldus), except for the forced swim test (FST) and tail suspension test, which were scored by observers blind to treatment conditions.

Social defeat stress and social interaction test. Social defeat was performed as previously described (Golden et al., 2011). Resident CD1 mice consistently displaying aggressive behaviors (<30 s on three screening sessions) were housed in cages fitted with perforated Plexiglas separators, which allow sensory contact without physical contact, and used to defeat the experimental mice. Specifically, adult (P70) C57BL/6 mice pretreated with VEH or FLX during adolescence (P35–P49) were exposed to a CD1 mouse for a 10-min-long defeat episode, during which time the C57BL/6 mouse was attacked and displayed subordinate posturing. To minimize physical injury and experimental animal attrition, the daily social defeat episode would be terminated immediately in the event that the CD1
mouse displayed extreme physical aggression (i.e., continuous biting after submissive posturing by the C57BL/6 mouse; for details, see Golden et al., 2011). At the end of the defeat episode, the experimental mouse was housed for the remainder of the day in the adjacent compartment next to the aggressor. This procedure was repeated for 10 consecutive days, with different aggressors used each day (Fig. 1a, schematic of experiment).

Control animals were housed in pairs, with one on each side of the perforated Plexiglas partition, and were handled daily (i.e., control housing conditions). Social avoidance was assessed the following day (day 11; P80) in a two-stage social interaction test. In the first 2.5 min trial (target absent), a VEH- or FLX-exposed C57BL/6 mouse was allowed to freely explore a square open-field arena (42 × 42 cm) containing a circular wire cage (9 cm diameter) apposed to one side (Fig. 1b). During the second 2.5 min trial (target present), the C57BL/6 mouse was reintroduced into this arena now containing a social target (unfamiliar CD1 mouse) within the circular wire cage. Time (in seconds) spent in the interaction zone (8 cm corridor) and the corner zones (10 × 10 cm) were the dependent variables (Berton et al., 2006).

**Forced swim test.** The FST is a behavioral procedure in which rodents are forced to swim under inescapable conditions. Initially, rodents engage in escape-like behaviors but eventually adopt a posture in which they make only the movements necessary to maintain their head/nose above water; however, antidepressant treatment can significantly increase their escape-directed behaviors, an effect that has been correlated with antidepressant efficacy in humans (Porsolt et al., 1977). In mice, this task was performed according to published protocols (Vialou et al., 2010; Warren et al., 2013). Briefly, mice were forced to swim once in a 4 L Pyrex glass beaker containing 3 L of water (24 ± 1°C) for 6 min. All cylinders were emptied and cleaned between mice. For rats, this is a 2 d procedure. Here, rats were placed in plastic cylinders (75 × 30 cm) filled to 54 cm depth with 24 ± 1°C water and forced to swim for 15 min. All cylinders were emptied and cleaned between rats. Twenty-four hours later, rats were retested for 5 min under identical conditions. At the end of each swimming period, mice and rats were removed from the water, dried with towels, and placed in a warmed enclosure for 30 min, then returned to their home cage. For both mouse and rat forced swimming sessions,
latency to become immobile (in seconds) and total immobility (in seconds) were the dependent variables. Latency to immobility was defined as the time at which the animal first initiated a stationary posture that did not reflect attempts to escape from the water. To qualify as immobility, this posture had to be clearly visible and maintained for ≥2.0 s. Last, for the rat FST, behavioral (5 s) swimming and climbing counts were also quantified (Dethke and Lucki, 1996; Parise et al., 2013).

**Elevated plus maze.** The EPM is a classic test of anxiety-like behavior (Montgomery, 1955). The mazes were made of gray plastic and consisted of two perpendicular, intersecting walkways (12 cm wide × 100 cm long for rats; 7 cm wide × 30 cm long for mice). One runway had tall walls (closed arm; 30 cm for rats; 25 cm for mice), and the other one had no walls (open arms). The arms were connected together by a central area, and the maze was elevated (1 m for rats; 50 cm for mice) from the floor. At the beginning of the test, under controlled light conditions (~90 lux), rodents were placed in the central area, facing one of the open arms, and the cumulative time spent in the closed and open arms was recorded (Iniguez et al., 2009). We also recorded the number of fecal boli as an additional index of anxiety (Ghisleni et al., 2008).

**Quantitative real-time reverse transcription PCR.** Separate groups of mice and rats were killed either 24 h (P50) or 3 weeks (P70) after the last VEH or FLX injection. The brains were rapidly removed, VTA punches (1 mm diameter for mice; 1.25 mm for rats) were collected, and samples were immediately placed on dry ice and stored at −80°C until assayed. Total RNA was isolated using RNeasy Micro kits (Qiagen), and cDNA was created from these samples using iScript cDNA synthesis kit (Bio-Rad). Quantitative real-time reverse transcription PCR (qRT-reverse transcription PCR) was performed in triplicate using 96-well PCR plates and RealMasterMix (Eppendorf) with an Eppendorf MasterCycler Realplex according to manufacturer’s instructions. Threshold cycle (Ct) values were measured using the supplied software and analyzed with the ∆∆Ct method (Vialou et al., 2010). Primer sequences for ERK1, ERK2, CREB, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are presented in Table 2.

**Western blotting.** Tissue punches of VTA (1.25 mm diameter) from adult rats (P70) pretreated with VEH or FLX during adolescence (P35-P49) were collected, immediately placed on dry ice, and stored at −80°C until assayed. Samples were then sonicated in a standard lysis buffer and protease inhibitors (Pierce Biotechnology), and reprobed with antibodies against total ERK1/2, CREB, and GAPDH. All antibodies were from Cell Signaling Technology and were used according to the manufacturer’s instructions in 5% milk dissolved in TBST. After further washes, membranes were incubated with peroxidase-labeled goat anti-rabbit IgG or horse anti-mouse IgG (1:40,000; Vector Laboratories). Bands were visualized with SuperSignal West Dura substrate (Pierce Biotechnology), quantified using NIH ImageJ, and normalized to GAPDH.

### Table 2. qPCR primers

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERK1 (Mapk1)</td>
<td>5′-TCCGCTAAGAAGTTATGAGGCGCA-3′</td>
<td>5′-GTGCGTGTGATAGGCAGATGGTGC-3′</td>
</tr>
<tr>
<td>ERK2 (Mapk3)</td>
<td>5′-GGCTTCTGCAATGCCTG-3′</td>
<td>5′-CACTGCACTCTCCGTGGAGTG-3′</td>
</tr>
<tr>
<td>CREB (Ceb)</td>
<td>5′-AGTTGAGGAGGAATGACCCAGAC-3′</td>
<td>5′-TGGCTGGTGAGGACCTCAAGAA-3′</td>
</tr>
<tr>
<td>GAPDH (GAPDh)</td>
<td>5′-CTGAGATGATATGGGCTTCTTC-3′</td>
<td>5′-AGAAAGGATCCAGTTCGCT-3′</td>
</tr>
</tbody>
</table>

**Pharmacological inhibition of ERK.** To begin establishing causal relationships between ERK activity and antidepressant efficacy, separate groups of C57BL/6 mice received an infusion of the ERK inhibitor U0126 into the VTA. U0126 or dimethylsulfoxide (DMSO; 1% in PBS; control) were delivered through an injector cannula in a total volume of 0.5 μL at a continuous rate of 0.1 μL/min. Concentration of U0126 (2 μg dissolved in 2 μL DMSO) was selected based on earlier in vivo studies (Huang and Lin, 2006). After U0126 delivery, the infusion needle remained in the guide cannula for 1 additional minute to ensure proper delivery. Mice were tested in the FST 7–8 d after cannula implantation, and 35 min after U0126 infusion.

**Viruses vectors and reversal experiments.** We used HSV vectors to directly increase (HSV-wtERK2) or decrease (HSV-dnERK2) ERK activity within the VTA. The construction of the vectors (HSV-GFP, HSV-wtERK2, and HSV-dnERK2) has been thoroughly described (Robinson et al., 1996; Neve et al., 1997), and the ERK2 viruses have been previously validated in vivo and in vitro (Krishnan et al., 2007; Iniguez et al., 2010c). All behavioral experiments were commenced 3 d after viral surgery, a time at which maximal transgene expression is observed (Carlezon et al., 1998; Barrot et al., 2002). Expression of the HSV-encoded transgenes was limited to an area of ~1 mm² around the injection site (see Fig. 5b), and viral expression was not apparent in either afferent or efferent regions of the injected area (Warren et al., 2011). Because the behavioral and pharmacological experiments indicated that antidepressant-like behaviors are accompanied by decreased VTA ERK expression, we sought to more directly assess the functional significance of ERK2 activity within the VTA as a mediator of behavioral responses to inescapable stress after FLX exposure. We thus conducted two separate experiments in C57BL/6 mice exposed to VEH or FLX during adolescence and microinjected them with HSV-GFP or HSV-wtERK2 in adulthood. In the first experiment (Table 1, group 14), adult mice pretreated with VEH or FLX during adolescence were microinjected with HSV-GFP or HSV-wtERK2 and exposed to a submaximal social defeat stress protocol (for schematic, see Fig. 5a) to examine whether increasing ERK activity would reverse the enduring antidepressant-like behavioral effects resulting from adolescent FLX exposure. In this test, mice were subjected to three defeat episodes within a single day (P69). The mice were placed into the CD1 aggressor’s cage for 5 min, followed by a 10 min break (in their home cage) between defeats. Each defeat episode was performed with different CD1 aggressors. This submaximal social defeat stress procedure has been successfully used to assess whether drug exposure or genetic manipulation (i.e., virus vectors) results in enhanced susceptibility to depression-like/avoirce behaviors (Krishnan et al., 2007, 2008). Social behavior was assessed 24 h later as described above. In the second experiment (Table 1, group 15), a separate group of VEH- or FLX-pretreated mice received HSV-GFP or HSV-wtERK2 microinjections into the VTA. A second model of depression, the tail suspension test (TST) 3 d later (P70) to determine whether increasing ERK activity would result in increased total immobility—a depression-like behavior (Steru et al., 1985). Specifically, the mice were suspended by their tail using adhesive tape (attached ~2 cm from the tip of the tail) secured to the edge of a table in a quiet room. The duration of immobility during the 6 min test was the dependent variable. If mice climbed up their tail, they were gently returned to the hanging position; mice that climbed up the adhesive tape more than two times were excluded from the experiment. Last, we microinjected drug-naïve P47 rats with the HSV vectors, and assessed their reactivity to the FST and the EPM to further examine how ERK regulation within the adolescent VTA influences behavioral responsivity to aversive circumstances (Table 1, groups 16 and 17). Here, P47 was chosen to match the FLX regimen schedule and behavioral testing at P50.

**Animal surgery.** Adult mice were anesthetized with a ketamine/xylazine mixture (100/10 mg/kg, i.p.) before implantation of a 26-gauge unilateral guide cannula (side counterbalanced across animals) fitted with obturators (Plastics One) that were secured to the skull after being positioned 1 mm directly above the VTA (anteroposterior, ~3.2 mm; mediolateral, +0.4 mm; dorsoventral, ~3.6 mm). For the viral vector studies, adult C57BL/6 mice pretreated with FLX during adolescence were anesthetized as described above, and bilaterally infused 0.5 μL of either HSV-
GFP or HSV-wtERK2 over 5 min into their VTA. We used established mouse VTA coordinates (anteroposterior, −3.2 mm; lateral, +1.0 mm; dorsoventral, −4.6 mm; 7° angle; Krishnan et al., 2008). For stereotaxic delivery of viral vectors in adolescent rats, P47 rats were anesthetized with a ketamine/xylazine mixture (90/10 mg/kg, i.m.) and were given atropine (0.25 mg/kg, s.c.) to minimize bronchial secretions. Rats received bilateral microinjections (1 μl per side over 10 min of HSV-GFP, HSV-wtERK2, or HSV-inERK2) into the rostral region of the VTA (anteroposterior, −4.9; lateral, +2.2; dorsoventral, −7.6 mm below dura; 10° angle; Bolanos et al., 2003a). The local anesthetic bupivacaine was applied directly along the wound edges to minimize any potential postoperative discomfort. The VTA injection sites were confirmed in all animals by standard histological methods (described below).

**Histology and transgene detection.** Twenty-four hours after behavioral testing with the ERK inhibitor (U0126), 0.5 μg of 4% methylene blue in saline was infused as described above; mice were then killed 1 h later, and their brains were extracted and stored in formalin for histological localization of infusion sites (see Fig. 4b). For the HSV experiments, immediately after behavioral testing, HSV-treated animals were given an overdose of pentobarbital and perfused transcardially with 20% glycerol. Coronal sections (rat, 45 μm; mouse, 30 μm) through the midbrain were obtained with a microtome and stored in 0.1 M sodium phosphate buffer with 0.05% azide. Sections were processed to examine the ability of HSV construct to drive the expression of GFP within the VTA as previously described (Itiúguez et al., 2010b). Midbrain free-floating coronal sections were processed for immunohistochemistry using rabbit anti-GFP (1:1000; Abcam) and TH (mouse; 1:5000, Millipore Bioscience Research Reagents), a marker of VTA dopamine neurons. Adjacent sections were blocked in 3% normal donkey serum (NDS) and incubated overnight in one of the primary antibodies mentioned above, along with 0.3% Triton X-100 (Fisher Scientific) and 1% NDS. Sections were incubated with anti-rabbit or anti-mouse secondary antibody (Jackson Immunoresearch) for 2 h at room temperature. Stained sections were then slide mounted (Fisher Scientific), dehydrated in ethanol, deaffeted in Citrosolv, and coverslipped with clear DPX adhesive (Sigma-Aldrich). Slides were then visualized and photographed using a fluorescence microscope and a digital camera. The total number of GFP-labeled cells throughout the VTA was determined in every sixth brain slice, and the percentage of those cells that coexpressed TH was calculated. Data obtained from animals with placements outside the intended brain regions (<10% of all experimental animals) were not included in the analyses.

**Statistical analyses.** Assignment of subjects to the various experimental conditions was random. Behavioral data were analyzed using ANOVA techniques, with drug, defeat stress, and virus as independent variables, and the presence of target as a repeated measure, followed by Tukey’s test, consisting of only a two-group comparison, was used for all other analyses. Statistical significance was defined as \( p < 0.05 \). Data are expressed as the mean ± SEM.

**Results**

**Adolescent FLX exposure regulates behavioral responses to aversive situations in adulthood**

**Social defeat stress**

Figure 1, c and d, shows the effects of FLX treatment during adolescence on social interaction after exposure to defeat stress in adulthood (n = 9 per group). Mice pre-exposed to VEH and FLX were subjected to 10 d (P70–P79) of social defeat (Fig. 1a), a stress regimen that induces a robust social avoidance in the majority of mice (Krishnan et al., 2007). Consistently, 24 h after the last defeat (P80), a two-way ANOVA revealed a significant drug pretreatment (VEH vs FLX) by the presence of social target (present vs absent) interaction \( F_{(1,16)} = 6.41, p < 0.02 \) with the time spent in the interaction zone. Post hoc comparisons indicated that the social avoidance phenotype was evident in the VEH-pretreated mice, as they spent significantly less time in the interaction zone (Fig. 1c) in the presence of the social target (target absent vs target present, \( p < 0.05 \)). On the contrary, mice pre-treated with FLX during adolescence spent as much time in the interaction zone in the absence, as in the presence, of the social target (\( p > 0.05 \)), suggesting that exposure to FLX early in life buffered the development of the stress-induced social avoidance phenotype in adulthood. Indeed, the FLX-pretreated mice spent significantly more time in the interaction zone when compared with the VEH-pretreated controls in the presence of the social target (between-group comparison, \( p < 0.01 \); Fig. 1c). Assessing time in the corner zones (Fig. 1d), an additional measure of social avoidance (Krishnan et al., 2007), yielded similar results (drug pretreatment by the presence of target interaction, \( F_{(1,16)} = 6.26, p < 0.02 \); VEH-pretreated mice spent significantly more time in the corners in the presence of the target (target absent vs present, \( p < 0.01 \)) or when compared with the FLX-pretreated group (between-group comparison, \( p < 0.01 \)).

To examine how FLX exposure during adolescence would influence baseline social interaction behavior in adulthood (in the absence of defeat stress), a second group of mice was exposed to VEH (n = 7) or FLX (n = 9) from P35 to P49, was later housed under control conditions for 10 d (P70–P79), and then tested for social interaction at P80. A two-way (drug pretreatment × target) ANOVA revealed a significant main effect of target presence \( (F_{(1,14)} = 33.29, p < 0.0001) \) on the time spent in the interaction zone (Fig. 1e). Here, both VEH- and FLX-pretreated mice spent significantly more time in the interaction zone in the presence of the social target (within-group comparison, \( p < 0.05 \), respectively). When assessing the time spent in the corner zones (Fig. 1f), a significant main effect of target presence \( (F_{(1,14)} = 7.20, p < 0.01) \) indicated that the VEH-pretreated mice spent significantly less time in the corner zones in the presence of the social target (target absent vs target present, \( p < 0.05 \)). No differences in time spent in the corners were observed in the FLX-pretreated mice (target absent vs target present, \( p > 0.05 \)). Lastly, no differences in total distance traveled (in centimeters) were observed between the groups (\( p > 0.05 \)) as a function of FLX pretreatment during the target-absent condition (Fig. 1g).

**Forced swim stress**

Similar to the results observed in the social defeat stress procedure, FLX exposure during adolescence prevented the expression of depression-like responses in adulthood (P70) as indexed in the FST (Fig. 2a,b). Exposure to FLX during adolescence resulted in a significant increase in the latency to become immobile \( (t_{(17)} = 3.89, p < 0.001; \) Fig. 2a, left) and an overall decrease in total immobility \( (t_{(17)} = 2.27, p < 0.03; \) Fig. 2a, right) when compared with the VEH-pretreated controls \( (n = 9–10\) per group). Next, we examined whether FLX exposure during adolescence would induce antidepressant-like effects in the FST following an even more chronic form of inescapable stress. Here, separate groups of mice were exposed to VEH (n = 8) or FLX (n = 10) from P35 to P49, and both sets of mice received 10 d of social defeat stress 3 weeks later (P70–P79). Twenty-four hours after the last defeat (P80), these mice were exposed to the FST (Fig. 2b). Again, we found that FLX pretreatment resulted in an overall antidepressant-like effect as inferred by an increase in latency to immobility \( (t_{(16)} = 2.48, p < 0.05; \) Fig. 2b, left), along with a decrease in total immobility \( (t_{(16)} = 2.80, p < 0.001; \) Fig. 2b, right) when compared with VEH-pretreated mice.

**Elevated plus maze**

FLX exposure during adolescence resulted in a significant increase in sensitivity to the anxiety-eliciting environment of the
Opposing role between FLX and stress on ERK signaling within the VTA

We then assessed the effects of FLX administration during adolescence on gene expression within the VTA, 24 h (short-term; n = 8 per group) and 3 weeks (long-term; n = 8–9 per group) after drug administration in C57BL/6 mice (Fig. 3a–c). No differences in ERK1 mRNA as a function of FLX treatment were observed at either short- or long-term points of assessment (p > 0.05, respectively; Fig. 3a). Conversely, chronic administration of FLX decreased ERK2 (t(14) = 2.72, p < 0.01) and CREB (t(14) = 2.46, p < 0.01) mRNA 24 h after the last injection (Fig. 3b,c, left), when compared with the VEH-pretreated mice. Three weeks after the last FLX injection (P70), decreases in ERK2 (t(15) = 2.28, p < 0.05; Fig. 3b, right) and CREB (t(15) = 1.7, p = 0.056) mRNA were observed when compared with the VEH-pretreated mice (Fig. 3c, right).

To determine the effect of stress in the absence of adolescent FLX treatment on ERK mRNA within the VTA, two separate groups of mice (n = 7 per group) were treated with VEH during adolescence and, as adults (P70–79), were either exposed to 10 d of social defeat stress or left undisturbed. Twenty-four hours after the last social defeat episode (P80), mice were killed and VTA was extracted and processed for qRT-reverse transcription PCR. No differences in ERK1 mRNA (Fig. 3d) were detected between stressed (social defeat) and nonstressed (control) mice (p > 0.05). On the other hand, defeated mice exhibited increased ERK2 mRNA (t(12) = 4.92, p < 0.01) when compared with the nondefeated controls (Fig. 3e). Together, these findings indicate that FLX and stress regulate ERK2 mRNA within the VTA in an opposing manner.

Functional role of ERK within the VTA in regulating mood-related behaviors

To more directly explore whether decreasing ERK activity within the VTA results in a similar antidepressant-like behavioral profile
as FLX administration, separate groups of mice were locally infused with DMSO (control; *n*/H11005 11) or the ERK inhibitor U0126 into the VTA (*n*/H11005 15), and were tested 35 min after infusion in the FST (Fig. 4). The infusion cannula tip locations are schematically depicted in Figure 4, a and b. Mice infused with U0126 showed significantly longer latency to immobility (*t*(24) = 2.39, *p* < 0.05; Fig. 4c), as well as a significant decrease in total immobility (*t*(24) = 2.31, *p* < 0.05; Fig. 4d) when compared with the DMSO-infused controls, thus displaying a classic antidepressant-like effect (Porsolt et al., 1977).

**Figure 3.** Regulation of ERK mRNA within the VTA of C57BL/6 male mice exposed to FLX and mice exposed to social defeat stress. a–c, Chronic FLX exposure (0, 10 mg/kg, bi-daily) during adolescence reduced ERK2 and CREB, but not ERK1, mRNA 24 h (short term; *n* = 8 per group) or 21 d (long term; *n* = 8–9 per group) after drug exposure when compared with the respective VEH-pretreated controls. d, e, Exposure to 10 d of social defeat stress significantly increased ERK2, but not ERK1, mRNA when compared with the nonstressed controls (*n* = 7 per group). Data are presented as the fold change normalized to GAPDH ± SEM. *p* < 0.05; β* p* = 0.056.

Reversal of the enduring FLX-induced antidepressant behavioral phenotype in adulthood

Based on our findings that FLX exposure during adolescence decreases sensitivity to social defeat and forced swimming stress, along with decreases in ERK2 activity within the VTA in adulthood, it was of interest to assess whether locally increasing ERK2 activity within this brain region would reverse this effect, thus increasing sensitivity to behavioral despair (Fig. 5). To this end, adult C57BL/6 mice pretreated with VEH or FLX as juveniles received a local microinjection of HSV-GFP or HSV-wtERK2 within the VTA, and their social behavior was assessed after a submaximal period of social defeat stress (Fig. 5a)—a stress regimen that is not sufficient to induce social avoidance in control mice (Krishnan et al., 2008). A three-way (drug × virus × target) ANOVA revealed a significant virus by target interaction for the time spent in the interaction zone (*F*(1,68) = 16.57, *p* = 0.0001). As expected, VEH-pretreated mice receiving microinjections of HSV-GFP (VEH-GFP; *n* = 9) did not differ in the time spent in the interaction zone (Fig. 5c), in the absence or presence of the social target (*p* > 0.05), thus indicating that submaximal social defeat was not sufficient to induce social avoidance in control mice, as previously reported (Krishnan et al., 2008; Iniguez et al., 2010b). On the contrary, VEH-pretreated mice overexpressing...
HSV-wtERK2 (n = 9) spent significantly less time in the interaction zone (Fig. 5c) in the presence of the social target (p < 0.05), or when compared with the VEH-pretreated mice expressing HSV-GFP (p < 0.01). Time spent in the corner zones (Fig. 5d) varied as a function of a virus by the presence of target interaction (F(1,68) = 18.73, p < 0.001). VEH-pretreated mice expressing HSV-wtERK2 spent significantly more time in the corners in the presence of the social target (p < 0.05), whereas those pretreated with FLX and microinjected with HSV-GFP (n = 11) spent significantly less time in the corner zones (Fig. 5d) in the presence of the social target (p < 0.05). Conversely, FLX-pretreated mice overexpressing HSV-wtERK2 (n = 9) spent significantly less time in the interaction zone in the presence of the target (p < 0.05; Fig. 5c), or when compared with FLX-pretreated mice expressing HSV-GFP (p < 0.05). These mice also spent significantly more time in the corners in the presence of the target (p < 0.05; Fig. 5d) or when compared with FLX-pretreated mice expressing HSV-GFP (p < 0.03). Together, this indicates that elevated ERK2 activity within the VTA enhances sensitivity to defeat stress, regardless of FLX pretreatment during adolescence. Importantly, no differences in distance traveled (in centimeters) were observed between the groups as a function of drug pretreatment or virus infection (p > 0.05) during the target-absent session (Fig. 5e).

To further delineate the role of increased ERK2 activity within the VTA in modulating responsiveness to other behavioral despair measures, we microinjected HSV-GFP or HSV-wtERK2 into the VTA of adult mice pretreated with VEH or FLX during adolescence, and assessed their behavioral reactivity to the TST (VEH+GFP, n = 8; VEH+wtERK2, n = 8; FLX+GFP, n = 8; or FLX+wtERK2, n = 9). A two-way (drug × virus) ANOVA revealed that the total time spent immobile on the TST was dependent on virus treatment (F(1,29) = 39.30, p < 0.0001), regardless of FLX pretreatment (drug main effect, p > 0.05; Fig. 5f). Specifically, mice overexpressing HSV-wtERK2 displayed greater immobility time (i.e., prodepressant effect) when compared with the HSV-GFP-microinjected mice. Planned comparisons revealed that FLX-pretreated mice expressing HSV-GFP spent significantly less time immobile when compared with the VEH-pretreated mice overexpressing HSV-GFP (p < 0.05), thus further confirming the enduring FLX-induced effect observed in the social defeat and FST paradigms (Figs. 1c,d, 2a,b).

Developmental role of ERK within the VTA in responses to aversive stimuli

Our data thus far indicate that repeated exposure to FLX during adolescence (P35–P49) results in decreased sensitivity to behavioral despair along with increased reactivity to anxiety-eliciting situations in adulthood. Our results also point to decreased ERK2 signaling within the VTA as a potential mediator of these lasting FLX-induced effects. To further compliment the present results, we examined the role of ERK activity within the adolescent VTA in modulating responses to stress. Accordingly, we assessed the influence of FLX on ERK signaling (mRNA and protein phosphorylation), and directly assessed the functional role of ERK in modulating responsiveness to stressful circumstances, using HSV vectors in adolescent rats.

Effects of FLX exposure during adolescence on ERK mRNA in the rat VTA

Adolescent rats were exposed to VEH or FLX from P35 to P49 and killed either 24 h (n = 9 per group; short-term) or 3 weeks (n = 7–8 per group; long-term) after drug exposure (Fig. 6a–c). Similar to our findings in C57BL/6 mice, FLX exposure did not influence ERK1 mRNA at any of the time points assessed (Fig. 6a). Conversely, FLX exposure significantly decreased ERK2 mRNA at 24 h (t(16) = 2.02, p < 0.03) and 3 weeks (t(13) = 2.05, p < 0.05) after drug administration when compared with the VEH-pretreated controls (Fig. 6b). FLX also decreased CREB mRNA (Fig. 6c), a downstream signaling substrate of ERK, at the short-term (t(16) = 2.31, p < 0.01) and long-term (t(13) = 2.21, p < 0.05) points of assessment, when compared with the VEH-pretreated controls.

Enduring effects of FLX exposure during adolescence on ERK-related protein phosphorylation in the rat VTA

We also examined ERK protein phosphorylation and related targets in a separate group of adult rats exposed to FLX during adolescence (Fig. 7). ERK-related signaling was assessed 3 weeks after VEH or FLX exposure (n = 8 per group), as inferred from the p levels of ERK1/2, as well as its downstream targets, RSK, MSK, CREB, and mTOR, within the VTA (Fig. 7a). FLX-
pretreated rats had a significant decrease in pERK2 (t(14) = 1.89, p < 0.04), pRSK (t(14) = 3.28, p < 0.01), pCREB (t(14) = 1.87, p < 0.04), and pmtOR (t(14) = 4.91, p < 0.01), while having no effects on pERK1 (p > 0.05) and pMSK (p > 0.05), when compared with the VEH-pretreated controls. No changes in total protein levels of ERK1, ERK2, CREB, or mTOR (p > 0.05, respectively; Fig. 7b) were detected when compared with VEH-pretreated controls (all normalized to GAPDH). To ensure consistency across the VTA samples collected, we also compared TH levels, a common marker for dopamine neu-
transgene expression was maximal on day 3 after infusion (data not shown), declining thereafter, and nondetectable 7 d after the microinjection, as previously shown in adults (Iñiguez et al., 2008b, 2010b; Warren et al., 2011). Confocal microscopy (Fig. 8b–d) revealed that the percentage of TH-positive neurons overexpressing GFP in the VTA (57%) was similar to previous findings (Iñiguez et al., 2008b, 2010b,c).

**Virus-mediated ERK2 expression in the adolescent rat VTA modulates reactivity to aversive situations**

Microinusions of HSV-GFP (n = 10), HSV-wtERK2 (n = 9), and HSV-dnERK2 (n = 9) within the VTA influenced behavioral reactivity to forced swimming stress in adolescent rats (Fig. 8e,f). The amount of time rats engaged in escape-directed behaviors varied as a function of virus treatment (latency to immobility, $F_{(2,25)} = 23.37$, $p < 0.001$; Fig. 8e). HSV-wtERK2-treated rats displayed shorter latencies to immobility when compared with the HSV-GFP-treated controls ($p = 0.051$). Conversely, adolescent rats receiving HSV-dnERK2 displayed longer latencies to immobility when compared with the HSV-GFP-treated rats ($p < 0.05$). Virus treatment also influenced total immobility ($F_{(2,25)} = 13.51$, $p < 0.01$; Fig. 8f), with HSV-wtERK2 showing higher (i.e., increased sensitivity to behavioral despair) and HSV-dnERK2-treated rats showing lower (i.e., decreased sensitivity to behavioral despair) total immobility when compared with the HSV-GFP-treated controls ($p < 0.05$, respectively). No differences in swimming or climbing counts, as a function of virus treatment, were observed between the groups ($p > 0.05$, respectively; data not shown).

We also assessed the ability of ERK2 to modulate anxiety-like behaviors, as measured in the EPM (n = 8–9 per group; Fig. 9). Time spent in the closed arms of the maze varied as a function of virus treatment ($F_{(2,22)} = 18.86$, $p < 0.001$). Adolescent rats microinjected with HSV-wtERK2 spent significantly less time in the closed arms ($p < 0.05$), whereas those receiving HSV-dnERK2 spent significantly more time in the closed arms ($p < 0.05$) when compared with the HSV-GFP-treated controls (Fig. 9a). Similarly, a one-way ANOVA revealed that time spent in the open arms (Fig. 9b) also varied as a function of virus treatment ($F_{(2,22)} = 10.43$, $p < 0.001$). Adolescent rats receiving HSV-wtERK2 spent significantly more time in the open arms when compared with the HSV-GFP-treated controls ($p < 0.05$), while no differences were observed between the HSV-GFP and HSV-dnERK2 groups ($p > 0.05$). The number of fecal boli was also quantified as an additional index of anxiety (Fig. 9c). Here, the number of fecal boli was also influenced by viral treatment ($F_{(2,22)} = 14.68$, $p < 0.01$). HSV-dnERK2-treated rats produced more fecal boli when compared with the HSV-GFP-treated controls ($p < 0.05$). Conversely, rats infused with the HSV-wtERK2 virus produced significantly fewer fecal boli than the HSV-GFP-treated controls ($p < 0.05$). No differences in total distance traveled (in centimeters) were observed between groups as a function of virus treatment ($p > 0.05$; Fig. 9d).

**Discussion**

Antidepressants are often prescribed to juveniles for the treatment of MDD (Safer, 2006), even though reliable evidence-based indications for their use and the neurobiological consequences of such treatments are lacking (Birmaher, 1998; Coyle et al., 2003). Thus, the present study was designed to assess enduring behavioral and biochemical consequences resulting from adolescent exposure to FLX. We show that chronic FLX administration during adolescence alters responsiveness to aversive circumstances while disrupting VTA ERK2 expression and related signaling in
adulthood. We demonstrate, using pharmacological (U0126) and gene-transfer approaches, that blockade of ERK2 activity can mimic the FLX-induced antidepressant-like behavioral profile, while enhancing ERK2 activity opposes the antidepressant-like behavioral profile.

Early-life exposure to FLX influenced responsivity to aversive situations 24 h after exposure to social defeat stress in adulthood. Adult mice pretreated with FLX during adolescence displayed decreased sensitivity to inescapable stress, as they did not exhibit the characteristic social avoidance induced by repeated episodes of social defeat (Berton et al., 2006), and by showing significantly higher latencies to immobility and decreased total immobility (i.e., antidepressant-like effect) in the forced swimming procedure (Porstelt et al., 1977). Paradoxically, these mice also displayed increased reactivity to anxiogenic stimuli—adult mice pretreated with FLX during adolescence spent significantly less time in the open arms of the EPM. Importantly, these enduring FLX-induced effects were not the result of changes in basal levels of social behavior (Fig. 1e) or general locomotor activity (Fig. 1g).

These data are in agreement with recent reports demonstrating that FLX exposure during periods before adulthood result in decreased reactivity to forced swimming stress (Karpova et al., 2009; Iniguez et al., 2010a), along with enhanced sensitivity to anxiety-inducing situations in adulthood (Homberg et al., 2011). Decreased sensitivity to inescapable stress after adolescent FLX pretreatment is consistent with reports showing that prenatal and preadolescent (P4–P21) FLX administration renders rodents more vulnerable to behavioral despair in adulthood (Ansorge et al., 2004; Lisboa et al., 2007; Popa et al., 2008), thus indicating that exposure to FLX across these developmental windows leads to distinct functional outcomes in adulthood (Airan et al., 2007; Olivier et al., 2011).

The neurobiological mechanisms underlying these FLX-induced effects are unknown. In adults, antidepressants regulate expression of complex intracellular signaling molecules such as BDNF/ERK/mTOR and CREB and their activity, factors associated with lasting synaptic changes influencing behavioral functioning (Duman and Monteggia, 2006; Krishnan and Nestler, 2008; Warren et al., 2011; Duman and Voleti, 2012). Several reports implicate ERK2, a key signaling molecule downstream of BDNF (Numakawa et al., 2010), in mediating the deleterious effects of stress (Eimat et al., 2003; Gourley et al., 2008; Iniguez et al., 2010b). Here we show that ERK2/CREB mRNA is decreased 24 h after chronic FLX exposure in the adolescent VTA. Unexpectedly, ERK2/CREB mRNA expression remained down-regulated in adulthood (Figs. 3a–c, 6). Because changes in gene expression do not necessarily translate into changes at the protein level and may not directly represent activity of these enzymes (Lee et al., 2003; Mehra et al., 2003), we assessed phosphorylation levels of key ERK-related proteins in adulthood. We found that exposure to FLX during adolescence decreased ERK2, RSK, CREB, and mTOR phosphorylation within the VTA, with no change in total levels of these proteins. These findings are consistent with studies demonstrating that FLX exposure blocks ERK phosphorylation in vivo (Fumagalli et al., 2005; Warren et al., 2011) and in vitro (Stepulak et al., 2008; Labasque et al., 2010), resulting in decreased ERK activity (Carlini et al., 2012). Our data, therefore, strongly indicate that the behavioral and therapeutic effects of FLX are mediated, at least in part, via decreases in ERK2 activity within the VTA. This is further supported by studies showing that decreased CREB expression, a downstream transcription factor of ERK (Carlezon et al., 2005), mediates antidepressant-like responses (Pliaakis et al., 2001; Conti et al., 2002; Newton et al., 2002; Wallace et al., 2009), whereas increased CREB activity within the VTA–nucleus accumbens circuit increases sensitivity to the adverse effects of inescapable stress (Pliaakis et al., 2001; Carlezon et al., 2005).

Because adolescent FLX treatment decreased reactivity to behavioral despair along with decreased ERK signaling within the VTA, it was of interest to determine whether blocking ERK would mimic, whereas increasing ERK activity would reverse, the enduring FLX-induced antidepressant-like behavioral profile. We took this approach because exposure to inescapable stress (i.e., social defeat) increases ERK2 mRNA (Fig. 3e) and ERK2 protein phosphorylation (Iniguez et al., 2010b), while inhibiting ERK (U0126) within the VTA results in antidepressant-like responses (Fig. 4c,d). Using virus vectors, we found that increasing ERK2 activity within the VTA of adult mice, regardless of adolescent FLX treatment, renders them susceptible to a submaximal episode of defeat stress, conditions that are not sufficient to
induce avoidance behaviors in control mice (Krishnan et al., 2007). Interestingly, FLX-pretreated mice receiving HSV-wtERK2 spent significantly less time interacting with a social target, thus reversing the long-lasting antidepressant phenotype induced by adolescent FLX exposure (Fig. 1.c,d). Importantly, this finding is reminiscent of the avoidance/depressive-like behavior exhibited by VEH-pretreated mice after exposure to 10 d of social defeat stress (Fig. 1c), or those receiving HSV-wtERK2 and exposed to the TST (Fig. 5f). Together, these findings strongly implicate ERK activity as a modulator of responsiveness to stress during adolescence (Figs. 3b, left, 6b, left) and adulthood (Iñiguez et al., 2010b).

To better delineate whether the behavioral effects of ERK activity within the VTA are age specific, we examined whether viral-mediated regulation of ERK2 activity would influence behavioral responses to aversive stimuli in drug-free adolescent rats (age-matched to FLX treatment). We decided to use rats, given their larger anatomy, thus making it easier to target the adolescent VTA. Here, we demonstrate, for the first time, that downregulating ERK2 levels with HSV-dnERK2 in adolescence recapitulates the antidepressant-like phenotype observed in juvenile rats and mice after FLX exposure (Reed et al., 2008; Iñiguez et al., 2010a; Brookshire and Jones, 2012). In contrast, increasing ERK2 levels using HSV-wtERK2 induces depressive-like responses (Fig. 8e,f) similar to those observed after chronic stress. Together, these findings indicate that ERK2 expression within the adolescent VTA regulates responsiveness to behavioral despair measures in an oppositional manner: decreased ERK activity reduces sensitivity to stress, as seen after FLX treatment, while increasing ERK activity induces a behavioral phenotype commonly seen after exposure to chronic stress, data that are consistent with the role of ERK within the VTA of adult rodents (Iñiguez et al., 2010b). Interestingly, the ability of ERK to regulate responses to anxiety-inducing situations appears age specific. In adolescents, FLX treatment or downregulation of ERK2 activity within the VTA results in anxiogenic-like effects (Fig. 9), whereas in adults similar responses are seen only after chronic stress or viral-mediated increases in ERK2 activity (Iñiguez et al., 2010b). Adolescent rats microinjected with HSV-dnERK2 spent significantly more time in the closed arms of the EPM and produced more fecal boli, both measures of anxiety, while those receiving HSV-wtERK2 displayed the opposite behavioral profile. The reason for these
age-dependent, paradoxical results is unknown—the distinction between anxiety and depression is not well understood, with no known biologically based differences (Berton and Nestler, 2006). It is conceivable that the same way that manipulations of ERK signaling in different brain regions (i.e., hippocampus vs VTA) bring about distinct behavioral phenotypes in response to stress (Shirayama et al., 2002; Berton et al., 2006; Duman and Monteggia, 2006; Krishnan et al., 2007), may also bring about opposite behavioral outputs within the same brain area as a function of age, such as increased sensitivity to stress accompanied by decreased anhedonia (Kaluff et al., 2006; Iniguez et al., 2010b). Together, these findings underscore the complexity of drug and intracranial manipulations in the immature brain (Spearr, 2000; Bolanos et al., 2003b, 2008; Warren et al., 2011), and detailed assessments of these phenomena across ages and different brain areas are needed. Furthermore, future investigations must examine the type of VTA neurons (i.e., dopaminergic vs GABAergic) that are primarily responsible for modulating the ERK2-mediated behavioral responses observed after FLX exposure, given that the pharmacological agent (U0126) and HSV vectors used in this investigation are not cell type specific.

Overall, our study shows that FLX administration during adolescence decreases sensitivity to behavioral despair, while enhancing responsiveness to anxiety-inducing situations in adulthood. This complex behavioral profile is accompanied by a sustained decrease in ERK2 activity within the VTA that, in turn, is capable of modulating behavioral responsiveness to emotion-eliciting environments in an age-specific manner. This study further points to a novel role for decreased ERK2 activity within the adolescent VTA in regulating the stress sequelae and the antidepressant effects of FLX. Within this context, these data may shed light into potential biomarkers underlying the etiology of mood dysregulation and antidepressant response during adolescence, which, in turn, may provide new modalities to more effectively treat mood-related disorders in juvenile populations.

References


Burke KC, Burke JD Jr, Regier DA, Rae DS (1990) Age at onset of selected mental disorders in five community populations. Arch Gen Psychiatry 47:511–518. CrossRef Medline


Fluoxetine exposure is restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 19:97–108. CrossRef Medline


